|
余兆松 |
||||
|
职称：教授兼分子医学研究中心主任 |
研究室名称：蛋白质体学与疾病生物标识研究室 |
|||
|
最高学歷：Ph.D. |
学校/国家：国立清华大学/中华民国 |
|||
|
分机号码：5171 |
电子邮件帐号： yusong@mail.cgu.edu.tw |
|||
|
个人网页网址： |
||||
|
研究室现有： 博士后研究员 ?3?人 |
博士班研究生? 2?人 |
硕士班研究生 2?人 |
||
|
专任研究助理? 4??人 |
大学部专题生? 2?人 |
updated at 2021/9/9 |
||
|
研究方向：
(1)以整合性体学研究模式研发口腔癌早期诊断生物标记及精準治疗标靶 口腔癌為国人好发癌症之一，男性发生率世界第一，已成為国人重大健康议题与医疗负担。然而在过去二十年间，口腔癌的早期侦测与精準标靶治疗进展非常有限，目前仍无有效的生物标记(biomarker)可应用於提高早期口腔癌检出率及辅助术后追踪，也缺乏针对口腔癌研发的标靶治疗(target therapy)策略以提升个人化的治疗效果。本实验室带领分子医学研究中心研究团队，参与美国领导的(国际癌症登月计画的一重要部分)，利用已建置成熟的多体学(multi-omics)分析技术平台，系统性深入研究国人口腔癌(病患癌组织与癌旁非肿瘤组织)的基因体(全外显子体及RNA定序)、蛋白体(定量蛋白体及磷酸化蛋白体)与代谢体(定量代谢体)全貌及其相关变异，透过整合性体学大数据分析以瞭解基因体变异所造成的蛋白体/代谢体变化，希望建构首个口腔癌 “多体学蓝图”(基因体→蛋白体→代谢体)，提供探索这些系统性变异对口腔癌发生进展的生物意义；同时结合标靶基因/蛋白质/代谢物定量技术及人源化肿瘤动物模式，研发可应用於作為早期侦测之生物标记与精準医疗用药标靶或指引。
(2)利用先進蛋白质體學分析技術研发可临床应用之癌症生物标记 癌症為人类主要死因之一。大部份癌症被诊断时皆為晚期，是癌症死亡率居高不下的主因。除了养成健康生活习惯外，早期诊断与有效治疗是目前对抗癌症的唯一有效方法。虽然有效的癌症生物标记(biomarker)並不多，抽取体液(血液、尿液、唾液等)檢查其中可能的癌症生物標記仍是最方便的初步篩檢方法。因此，找尋新穎且更為有效的体液生物標記是對早期診斷癌症非常重要的課題。以質譜學為基礎之蛋白质體學為近年來新興學門，由於具備高靈敏度、高精確度與高通量之特性，被學界寄予厚望可以用來系統性分析(包括定性与定量)癌症相關樣本中蛋白质，藉以找尋與驗證具高應用價值的癌症生物標記。本實驗室與本校多位同仁合作，共同建立，发展多種蛋白质體相關定性與定量分析技術平台，分別利用三種生物材料(癌症病患、及)找寻癌症生物标记及分析癌症之异常分子调节机转。本实验室目前针对国人数种好发癌症，包括口腔癌、大肠癌、肝癌及胰臟癌同步进行研究，長期目標在於發展出可實際應用於臨床偵測早期癌症及其復發的体液生物標記，同時發展可快速方便檢驗這些生物標記的方法。目前已於2016/10发表，领先其他国际团队，已获多国专利，并技术移转给本土新创生技公司，进行后续免疫检测试剂开发(ELISA及试纸型快筛)与临床试验，此产学合作成果亦获得生技相关奖项的肯定，包括 「」(2019/07)、「」(2019/11)、 「」(2021/08) 及合作新创生技公司获「第16屆国家新創獎-初创公司奖」(2019/12)。该ELISA试剂组已於2020/12/04完成欧盟註册 (註册号00159706)，产物已可以进入欧盟销售。此為国人自行成功开发的第一个口腔癌生物标记免疫检测商品化试剂组，可為后续一系列衍生或相关检测产物重要参考品，具指标性意义，对提升防治国人口腔癌的检测能力预期将有重大影响。而也已於2011/05发表，亦获多国专利及技术移转给本土新创生技公司，进行后续免疫检测试剂开发与临床试验。
(3)研發重要醫用或研究用蛋白质的核酸适体(Aptamer) 核酸适体(Aptamer)是具有独特立体结构的单链RNA或DNA(长度在20～80个硷基)、可与特定分子标靶以构型互补模式结合，此结合作用与抗体--抗原反應類似，因此核酸适体具有發展成為與抗體類似的拮抗劑或分子靶向工具的高應用潛能。本實驗室已建立以PCR為基礎的核酸适体的高效篩選技術SELEX（systematic evolution of ligands by exponential enrichment），將針對重要醫用或研究用蛋白质開發高親和力核酸适体，提供研发疾病检测或标靶治疗的新颖分子工具。 ? (4)應用蛋白质體學技術研究細胞訊息傳遞分子機制 本實驗室以累積多年之蛋白质酵素分離純化鑑定經驗，過去十多年中投入並成功研發以質譜學為基礎之多種蛋白质體相關定性與定量分析技術。利用這些強大效能蛋白质體分析工具，我們可以重新擴大研究檢視各種細胞內關鍵訊息傳導路徑、發現新穎蛋白质交互作用及分析各種蛋白质後轉譯修飾作用，這些可能性大幅提升了細胞生物學領域研究的廣度與深度。 ? |
||||
|
最近五年所发表论文：*corresponding author 1.????? Wu CC#, Lu YT#, Yeh TS#, Chan YH, Dash S, Yu JS* (2021) Fucosylated SERPINA1 is a novel serum marker for pancreatic cancer revealed by lectin affinity capture coupled with iTRAQ-based quantitative glycoproteomics approach. Int J Mol Sci 2021 Jun 4; 22(11), 6079. doi: 10.3390/ijms22116079. 2.????? ● Liu JC, Chen YT, Hsieh YJ, Wu CC, Huang MC, Hsu YC, Wu CT, Chen CK, Dash S, Yu JS* (2021) Association of urinary ketamine and APOA1 levels with bladder dysfunction in ketamine abusers revealed via proteomics and targeted metabolite analyses. Scientific Reports 2021 May 5;11(1):9583. doi: 10.1038/s41598-021-89089-4. 3.????? Chiang SF+, Huang HH+, Tsai WS+, Tan BCM, Yang CY, Huang PJ, Chang IYF, Lin J, Lu PS, Chin E, Liu YH, Yu JS, Chiang JM, Hung HY, You JF, Liu H*. (2021) Comprehensive functional genomic analyses link APC somatic mutation and mRNA-miRNA networks to the clinical outcome of stage-III colorectal cancer patients. Biomedical Journal Available online 16 March 2021. doi: 10.1016/j.bj.2021.03.001 4.????? Wu CP*, Hung CY, Lusvarghi S, Chang YF, Hsiao SH, Huang YH, Hung TH, Yu JS, Ambudkar SV (2021) Overexpression of human ABCB1 and ABCG2 reduces the susceptibility of cancer cells to the histone deacetylase 6-specific inhibitor citarinostat. Int J Mol Sci 2021 Mar 5; 22(5), 2592. doi: 10.3390/ijms22052592. 5.????? Liu CC#, Yang YH#, Hsiao YC, Wang PJ, Liu JC, Liu CH, Hsieh WC, Lin CC, Yu JS* (2021) Rapid and efficient enrichment of snake venoms from human plasma by a strong cation exchange tip column to improve snakebite diagnosis. Toxins 2021 Feb 13; 13(2), 140. doi: 10.3390/toxins13020140. 6.????? ●● Chang YT, Chu LJ, Liu YC, Chen CJ, Wu SF, Chen CH, Chang IYF, Wang JS, Wu TY, Dash S, Chiang WF, Chiu SF, Gou SB, Chien CY, Chang KP, Yu JS*. (2020) Verification of saliva matrix metalloproteinase-1 as a strong diagnostic marker of oral cavity cancer. Cancers (Basel). 2020 Aug 13; 12(8):E2273. doi: 10.3390/cancers12082273. 7.????? Chen YT#, Chang IYF#, Kan CH, Liu YH, Kuo YP, Tseng HH, Chen HC, Liu H, Chang YS, Yu JS, Chang KP, Tan BCM*. circRNAome profiling unveils a novel oncogenic circFLNB circuit in oral cancer. (2020) Cells. 2020 Aug 10; 9(8):E1868. doi: 10.3390/cells9081868 8.????? ● Lin YH*, Wu CC, Su WT, Tseng PC, Hsueh YY, Hsiao YC, Chang KP, Yu JS*, Chuang YR. (2020) Target peptide enrichment microfluidic chip for rapid detection of oral squamous cell carcinoma using stable isotope standards and capture by anti-peptide antibodies. Sensors and Actuators B: Chemical 2020 Nov 1, 322:128607 9.????? Wu CP*, Hung CY, Lusvarghi S, Huang YH, Tseng PJ, Hung TH, Yu JS, Ambudkar SV. (2020) Overexpression of ABCB1 and ABCG2 contributes to reduced efficacy of the PI3K/mTOR inhibitor samotolisib (LY3023414) in cancer cell lines. Biochemical Pharmacology 2020 Jul 4:114137. doi: 10.1016/j.bcp.2020.114137. 10.? Hsueh PC, Wu KA, Yang CY, Hsu CW, Wang CL, Hung CM, Chen YT, Yu JS, Wu CC* (2020) Metabolomic profiling of parapneumonic effusion reveals a regulatory role of dipeptides in interleukin-8 production in neutrophil-like cells. Analytica Chimica Acta 2020 Sep 1;1128:238-250. doi: 10.1016/j.aca.2020.06.022. 11.? Chakraborty A, Lin WC, Lin YT, Huang KJ, Wang PY, Chang YF, Wang HI, Ma KT, Wang CY, Huang XR, Lee YH, Chen BC, Hsieh YJ, Chien KY, Lin TY, Liu JL, Sung LY, Yu JS, Chang YS, Pai LM*. (2020) SNAP29 mediates the assembly of histidine-induced CTP synthase filaments in proximity to the cytokeratin network. J Cell Sci 2020 May 11;133(9):jcs240200. doi: 10.1242/jcs.240200. 12.? Hsiao TF#, Wang CL#, Wu YC, Feng HP, Chiu YC, Lin HY, Liu KJ, Chang GC, Chien KY, Yu JS, Yu CJ*. (2020) Integrative omics analysis reveals soluble cadherin-3 as a survival predictor and an early monitoring marker of EGFR tyrosine kinase inhibitor therapy in lung cancer. Clin Cancer Res. 2020 Jul 1;26(13):3220-3229. doi: 10.1158/1078-0432.CCR-19-3972. 13.? Liu CC#, Chou YS#, Chen CY, Liu KL, Huang GJ, Yu JS, Wu CJ, Liaw GW, Hsieh CH*, Chen CK*. (2020) Pathogenesis of local necrosis induced by Naja atra venom: Assessment of the neutralization ability of Taiwanese freeze-dried neurotoxic antivenom in animal models. PLOS Neglected Tropical Diseases. 2020 Feb 7;14(2):e0008054. doi: 10.1371/journal.pntd.0008054. 14.? ●● Hsiao YC, Lin SY, Chien KY, Chen SF, Wu CC, Chang YT, Chi LM, Chu LJ, Chiang WF, Chien CY, Chang KP, Chang YS, Yu JS* (2020) An immuno-MALDI mass spectrometry assay for the oral cancer biomarker, matrix metalloproteinase-1, in dried saliva spot samples. Anal Chim Acta 1100:118-130. doi: 10.1016/j.aca.2019.12.006. 15.? ● Chi LM#, Hsiao YC#, Chien KY#, Chen SF, Chuang YN, Lin SY, Wang WS, Chang IYF, Yang C, Chu LJ, Chiang WF, Chien CY, Chang YS, Chang KP*, Yu JS*. (2020) Assessment of candidate biomarkers in paired saliva and plasma samples from oral cancer patients by targeted mass spectrometry. J Proteomics. 2020 Jan 16;211:103571. doi: 10.1016/j.jprot.2019.103571. 16.? Lin WR*, Chiang JM, Lim SN, Su MY, Chen TH, Huang SW, Chen CW, Wu RC, Tsai CL, Lin YH, Alison MR, Hsieh SY, Yu JS, Chiu CT, Yeh CT. (2019) Dynamic bioenergetic alterations in colorectal adenomatous polyps and adenocarcinomas. EBioMedicine. 2019 Jun;44:334-345. doi: 10.1016/j.ebiom.2019.05.031. 17.? Yu J-S. (2019) From discovery of tyrosine phosphorylation to targeted cancer therapies: The 2018 Tang Prize in Biopharmaceutical Science. Biomedical Journal 2019 Apr; 42(2), 80-83 doi: 10.1016/j.bj.2019.03.004. (Invited article) 18.? Chen Y-T*, Tsai C-H, Chen C-L, Yu J-S, Chang Y-H*. (2019) Development of biomarkers of genitourinary cancer using mass spectrometry-based clinical proteomics. J. Food Drug Anal. 2019 Apr; 27(2):387-403. doi: 10.1016/j.jfda.2018.09.005. 19.? Chen Y-T*, Huang H-C, Hsieh Y-J, Fu S-H, Li L, Chen C-L, Chu L-J, Yu J-S. (2019) Targeting amine- and phenol-containing metabolites in urine by dansylation isotope labeling and liquid chromatography mass spectrometry for evaluation of bladder cancer biomarkers. J. Food Drug Anal. 2019 Apr; 27(2): 460-474. doi: 10.1016/ j.jfda.2018.11.008. 20.? Chou PH, Liao WC; Tsai KW, Chen KC Yu JS, Chen TW*. (2019) TACCO, a database connecting transcriptome alterations, pathway alterations and clinical outcomes in cancers. Scientific Reports 2019 Mar 7;9(1):3877. doi: 10.1038/s41598-019-40629-z. 21.? Wang P#, Geng J#, Gao J, Zhao H, Li J, Shi Y, Yang B, Xiao C, Linghu Y, Sun X, Chen X, Hong L, Qin F, Li X, Yu JS, You H, Yuan Z, Zhou D, Johnson RL, Chen L* (2019) Macrophage achieves self-protection against oxidative stress-induced ageing through Mst-Nrf2 axis. Nature Communications 2019 Feb 14;10(1):755. doi: 10.1038/s41467-019-08680-6. 22.? Hsu C-W#, Chen Y-T#, Hsieh Y-J, Chang K-P, Hsueh P-C, Yu J-S, Chang Y-S, Li L*, Wu C-C* (2019) Integrated analyses utilizing metabolomics and transcriptomics reveal perturbation of the polyamine pathway in oral cavity squamous cell carcinoma. Anal Chim Acta 2019 Mar 7;1050:113-122. doi: 10.1016/j.aca.2018.10.070. 23.? Lin Y-H*, Chang H-Y, Wu C-C, Wu C-W, Chang K-P, Yu J-S*. (2019). BRAF protein immunoprecipitation, elution, and digestion from cell extract using a microfluidic mixer for mutant BRAF protein quantification by mass spectrometry. Anal. Bioanal. Chem. 2019 Feb;411(5):1085-1094. doi: 10.1007/s00216-018-1536-2. 24.? Lee C-C#, Hsieh Y-J#, Chen S-W, Fu S-H, Hsu C-W, Wu C-C, Han W, Li Y, Tao H, Chang Y-S, Yu J-S, Li L*, Chang C-H*, Chen Y-T*. (2018) Bretschneider solution-induced alterations in the urine metabolome in cardiac surgery patients. Scientific Reports 2018 Dec 11;8(1):17774. 25.? ●● Liu C-C#, Yu J-S#, Wang P-J, Hsiao Y-C, Liu C-H, Chen Y-C, Lai P-F, Hsu C-P, Fann W-C, Lin C-C*. (2018) Development of sandwich ELISA and lateral flow strip assays for diagnosing clinically significant snakebite in Taiwan. PLOS Neglected Tropical Diseases. 2018 Dec 3;12(12):e0007014. #Contributed equally 26.? Lin W-C, Chakraborty A, Huang S-C, Wang P-Y, Hsieh Y-J, Chien K-Y, Lee Y-H, Chang C-C, Tang H-Y, Lin Y-T, Tung C-S, Luo J-D, Chen T-W, Lin T-Y, Cheng M-L, Chen Y-T, Yeh C-T; Liu J-L, Sung L-Y, Shiao M-S, Yu J-S, Chang Y-S, Pai L-M*. (2018) Histidine-dependent protein methylation is required for compartmentalization of CTP synthase. Cell Reports 2018 Sep 4;24(10):2733-2745.e7. 27.? Wu CP*, Hsieh YJ, Murakami M, Vahedi S, Hsiao SH, Yeh N, Chou AW, Li YQ, Wu YS, Yu JS, Ambudkar SV. (2018) Human ATP-binding cassette transporters ABCB1 and ABCG2 confer resistance to histone deacetylase 6 inhibitor ricolinostat (ACY-1215) in cancer cell lines. Biochem Pharmacol. 2018 Jul 17. 155:316-325. 28.? Liu C-C#, Lin C-C#, Hsiao Y-C, Wang P-J, Yu J-S*. (2018) Proteomic characterization of six Taiwanese snake venoms: Identification of species-specific proteins and development of a SISCAPA-MRM assay for cobra venom factors. J. Proteomics 2018 Sep 15, 187:59-68. 29.? Huang Y-H, Lin K-H, Yu J-S, Wu T-J, Lee W-C, Chao C-K, Pan T-L, Yeh C-T*. (2018) Targeting HSP60 by subcutaneous injections of jetPEI/HSP60-shRNA destabilizes cytoplasmic survivin and inhibits hepatocellular carcinoma growth. Mol. Carcinog. 2018 Apr 19. 57:1087–1101. 30.? Chen C-T, Liu C-C, Yu J-S, Li H-H, Lai M-C*. (2018) Integrated omics profiling identifies hypoxia-regulated genes in HCT116 colon cancer cells J. Proteomics 188:139-151. 31.? ● Chu LJ#, Hsiao YC#, Chiang WF#, Tsai CJ, Lin SY, Chang KP, Chien CY, Yu JS*. (2018) Use of saliva protein biomarkers for diagnosis of oral cavity cancer. International Journal of Head and Neck Science June 2018; 2(2): 56-68. (Invited review article) 32.? Tsai C-H,#, Chen Y-T*,#, Chang Y-H#, Hsueh C, Liu C-Y, Chang Y-S, Chen C-L*, Yu J-S* (2018) Systematic verification of bladder cancer-associated tissue protein biomarker candidates in urine specimens. Oncotraget 2018 Jul 20;9(56):30731-30747. 33.? Lai YH, Liu H, Chiang WF, Chen TW, Chu LJ, Yu JS, Chen SJ, Chen HC, and Tan BC*. (2018) MiR-31-5p-ACOX1 axis enhances tumorigenic fitness in oral squamous cell carcinoma via the promigratory prostaglandin E2. Theranostics 2018 Jan 1;8(2):486-504. 34.? ●● Hsiao YC#, Chu LJ#, Chen YT, Chi LM, Chien KY, Chiang WF, Chang YT, Chen SF, Wang WS, Chuang YN, Lin SY, Chien CY, Chang KP, Chang YS, and Yu JS*. (2018) Variability assessment of 90 salivary proteins in intra-day and inter-day samples from healthy donors by multiple reaction monitoring-mass spectrometry. (2018) Proteomics-Clin Appl. 2018 Mar;12(2). doi: 10.1002/prca.201700039. 35.? Wu CC#, Lin JD#, Chen JT, Chang CM, Weng HF, Hsueh C, Chien HP and Yu JS*. (2018) Integrated analysis of fine-needle-aspiration cystic fluid proteome, cancer cell secretome, and public transcriptome datasets for papillary thyroid cancer biomarker discovery. Oncotarget 9:12079-12100. 36.? Liu CC, You CH, Yu JS*, Huang GJ, Liu CH, Wang PJ, and Lin CC*. (2017) Analysis of the efficacy of Taiwanese freeze neurotoxic antivenom against Southeast Asian cobra venoms through proteomics and animal model approaches. PLOS Neglected Tropical Disease. 2017 Dec 15;11(12): e0006138. 37.? ●● Hsiao Y-C, Chi L-M, Chien K-Y, Chiang W-F, Chen S-F, Chuang Y-N, Lin S-Y, Wu C-C, Chu LJ, Chen Y-T, Chia S-L, Chien C-Y, Chang K-P, Chang Y-S, and Yu J-S*. (2017) Development of a multiplexed assay for oral cancer candidate biomarkers using peptide immunoaffinity enrichment and targeted mass spectrometry. Mol. Cell. Proteomics 2017 Oct;16(10):1829-1849. 38.? ●● Chen TW#, Lee CC#, Liu H#, Wu CS#, Pickering CR#, Huang PJ, Wang J, Chang IY, Yeh YM, Chen CD, Li HP, Luo JD, Tan BC, Chan TEH, Hsueh C, Chu LJ, Chen YT, Zhang B, Yang CY, Wu CC, Hsu CW, See LC, Tang P, Yu JS, Liao WC, Chiang WF, Rodriguez H, Myers JN, Chang KP*, Chang YS*. (2017) APOBEC3A is an oral cancer prognostic biomarker in carriers of an APOBEC deletion polymorphism. Nature Communications. 2017 Sep 6;8(1):465. 39.? ● Hsiao YC#, Chu LJ#, Chen JT, Yeh TS and Yu JS*. (2017) Proteomic profiling of the cancer cell secretome: informing clinical research. Expert Review of Proteomics (Invited review article) 2017 Sep;14(9):737-756. 40.? ●● Peng Y#, Zhang M#, Zheng L#, Liang Q#, Li H#, Chen J-T, Guo H, Yoshina S, Chen Y-Z, Zhao X, Wu X, Liu B, Mitani S, Yu J-S, Ding Xue*. (2017) Cysteine protease cathepsin B mediates radiation-induced bystander effects. Nature 547(7664), 458–462 (27 July 2017) 41.? Cheng JC*, Tseng CP, Liao MH, Peng CY, Yu JS, Chuang PH, Huang JT, Chen JJW. (2017) Activation of hepatic stellate cells by the ubiquitin C-terminal hydrolase 1 protein secreted from hepatitis C virus-infected hepatocytes. Scientific Reports. 2017 June 30;7:4448. doi:10.1038/s41598-017-04259-7 42.? ● Hsieh Y-J#, Chien K-Y#, Yang I-F, Lee I-N, Wu C-C, Huang T-Y, and Yu J-S* (2017) Oxidation of protein-bound methionine in Photofrin-photodynamic therapy-treated human tumor cells explored by methionine-containing peptide enrichment and quantitative proteomics approach. Scientific Reports 2017 May 2;7(1):1370. doi: 10.1038/s41598-017-01409-9. 43.? Shao CH, Chen CL, Lin JY, Chen CJ, Fu SH, Chen YT, Chang YS, Yu JS, Tsui KH, Juo CG*, Wu KP*. (2017) Metabolite marker discovery for the detection of bladder cancer by comparative metabolomics. Oncotarget. 2017 Mar 21. 2017; 8:38802-38810 doi: 10.18632/oncotarget.16393. 44.? Chen Y-T*, Chen H-W, Wu C-F, Chu L-J, Chiang W-F, Wu C-C, Yu J-S, Tsai C-H, Liang K-H, Chang Y-S, Wu M, Ou Yang W-T. (2017) Development of a multiplexed LC-MRM/MS method for evaluation of salivary proteins as oral cancer biomarkers. Mol. Cell. Proteomics 2017 May;16(5):799-811. 45.? ● Lin YT, Chien KY, Wu CC, Chang WY, Chu LJ, Yeh CT*, Yu JS*. (2017) Super-SILAC mix coupled with SIM/AIMS assays for targeted verification of phosphopeptides discovered in a large-scale phosphoproteome analysis of hepatocellular carcinoma. J. Proteomics. 2017 Mar 22;157:40-51. 46.? Chung I-C, OuYang C-N, Yuan S-N, Li H-P, Chen J-T, Shieh H-R, Chen Y-J, Ojcius DM, Yu J-S, Chang Y-S, Chen L-C*. (2016) Pyk2 activates the NLRP3 inflammasome by directly phosphorylating ASC and contributes to inflammasome-dependent peritonitis. Scientific Reports 2016 Oct 31; 6:36214. 47.? ●● Yu JS#, Chen YT#, Chiang WF#, Hsiao YC#, Chu LJ#, See LC, Wu CS, Tu HT, Chen HW, Chen CC, Liao WC, Chang YT, Wu CC, Lin CY, Liu SY, Chiou ST, Cha SL, Chang KP, Chien CY, Chang SW, Chang CJ, Young JD, Pao CC, Chang YS*, Hartwell LH* (2016) Saliva Protein Biomarkers to Detect Oral Squamous Cell Carcinoma in a High-Risk Population in Taiwan. Proc Natl Acad Sci USA. 2016 Oct 11;113(41):11549-11554. (#Co-first authors) 48.? Hsu CH, Hsu CW, Hsueh C, Wang CL, Wu YC, Wu CC, Liu CC, Yu JS, Chang YS, Yu CJ.* (2016) Identification and characterization of potential biomarkers by quantitative tissue proteomics of primary lung adenocarcinoma. Mol. Cell. Proteomics 2016 Jul;15(7):2396-410. 49.? ● Chen H#, Hsiao Y-C#, Chiang S-F, Wu C-C, Lin Y-T, Liu H, Zhao H, Chen J-S, Chang Y-S, and Yu J-S*. (2016) Quantitative analysis of wild-type and V600E mutant BRAF proteins in colorectal carcinoma using immunoenrichment and targeted mass spectrometry. Anal. Chim. Acta 2016 Aug 24; 933:144-55. 50.? Wang C-I, Chan Y-Y, Wang C-L, Yu J-S, Chang Y-S, and Yu C-J*. (2016) mTOR regulates proteasomal degradation and Dp1/E2F1-mediated transcription of KPNA2 in lung cancer cells. Oncotarget 2016 May 3;7(18):25432-42. 51.? Wu C-P*, Hsieh Y-J, Hsiao S-H, Su C-Y, Li Y-Q, Huang Y-H, Huang C-W, Hsieh C-H, Yu J-S and Wu Y-S*. (2016) Human ATP-Binding Cassette transporter ABCG2 confers resistance to CUDC-907, a dual inhibitor of histone deacetylase and phosphatidylinositol 3-kinase. Mol. Pharm. 2016 Mar 7;13(3):784-94. ? 专利: 1.????? Yu JS, Chang KP. (2012) Method of detecting malignancy of nasopharyngeal carcinoma and a nasopharyngeal carcinoma malignancy biomarker. United States Patent, US8,148,059B2, Apr. 3, 2012. Patent period 2012/4/3~2029/10/30 2.????? 陈怡婷、余兆松、陈建纶、张玉生 (2013) 膀胱癌之生物標記及其檢測方法。中华民国專利發明第I390204号, 专利权期间: 2013/03/21-2030/2/10 3.????? 余兆松、张雅婷、吴治庆、石宜铭、张玉生 (2013) 胰臟癌之血清生物检测标誌及其应用。中华民国專利發明第I408370号, 专利权期间: 2013/9/11~2031/5/18 4.????? 余兆松、蔡名鸿、谢玲玲 (2014) 大腸直腸癌遠端轉移之血漿生物標誌及其應用。中华民国專利發明第I444386号, 专利权期间: 2014/7/11~2032/4/9 5.????? Chao-Sung Lai, Jau-Song Yu, Yu-Sun Chang, Po-Lung Yang, Tseng-Fu Lu, Yi-Ting Lin, Wen-Yu Chuang, Ting-Chun Yu, I-Shun Wang, Jyh-Ping Chen, Chou Chien (2014) Surface treatment method by using the NH3 plasma treatment to modify the sensing thin-film. United States Patent, US8741679 B2, June 3, 2014. Patent period 2014/6/3~2032/5/8 6.????? Jau-Song Yu, Ya-Ting Chang, Chih-Ching Wu, Yi-Ming Shyr, Yu-Sun Chang (2014) A method for detecting pancreatic cancer using the serological marker ULBP2. European patent, EP2525227B1, Patent period: 2/16/2015~5/16/2032 (Poland), 11/19/2014~5/16/2032 (France), 12/11/2014~5/16/2032 (Germany), 1/20/2015~5/16/2032 (Italy), 11/19/2014~5/16/2032 (United Kingdom), 1/13/2015~5/16/2032 (Spain) 7.????? 陈怡婷、余兆松、陈建纶、张玉生 (2016) 尿液生物標記作為預測膀胱及腎臟癌的用途。中华民国專利發明第I522367号, 专利权期间: 2016/2/21~2033/4/11 8.????? Jau-Song Yu, Wei-Fan Chiang, Yi-Ting Chen, Yu-Sun Chang, Lai-Chu See, Yung Chin Hsiao, Kai-Ping Chang. (2016) Apparatus and methods for detecting oral squamous cell carcinoma. US provisional application. No. 62309766 (application date: 2016/03/17) 9.????? Yu-Sun Chang, Jau-Song Yu, Yi-Ting Chen, Wei-Fan Chiang, Yung Chin Hsiao, Lai-Chu See, Kai-Ping Chang. (2017) Methods for cancer diagnosis and prognosis. International application (PCT) No. PCT/US17/22853 (application date: 2017/03/17) 10.? 余兆松、陈怡婷、蔣維凡、蕭永晉、張玉生、史麗珠、張凱評 (2019) 一種用以診斷及預斷癌症的方法。中华民国專利發明第I651536号, 专利权期间: 2019/2/21~2037/3/15 11.? Err-Cheng Chan, Kuei-Tien Chen, Jau-Song Yu, Yu-Sun Chang Jinn-Shiun Chen. (2017) Serological markers for detecting colorectal cancer and their application for inhibiting colorectal cancer cells. United States Patent, US 9,835,636 B2, Dec. 5, 2017. Patent period: 2011/10/4-2031/10/3 12.? Yu-Sun Chang, Jau-Song Yu, Yi-Ting Chen, Wei-Fan Chiang, Yung Chin Hsiao, Lai-Chu See, Kai-Ping Chang. (2020) Methods for cancer diagnosis and prognosis. European patent, EP3430406B1, Patent period: 2020/12/02~2037/3/17. (application date: 2017/03/17; application No.17767588.1) 13.? 张雅婷/余兆松/王俊胜/吴淑芳/陈致儒/刘晏君 (2021) 第一型基质金属蛋白酶的单株抗体、其检测套组及其检测方法 (Matrix metalloproteinase-1 monoclonal antibody, detection kit and detection method thereof) 中华民国專利(申請案号：109106582, 申请日2020/02/27)(审定核准日2021/05/14) ? 技转与产学合作: 1.「口腔癌检测方法的相关技术」技转世延生医股份有限公司, 2017/1/23-2023/1/22. 产学合作计画 「口腔癌生物标誌免疫检测试剂开发」, 2017/6/1-2020/12/31. 2.「胰臟癌之血清生物检测标誌及其应用」技转世延生医股份有限公司, 2020/01/10~2030/01/10. 「胰臟癌症生物标誌免疫试剂开发测试」, 2020/9/1-2022/8/31. ? ? |
||||
| ? | ? | ? | ? | ? |
?
?